News | February 17, 2023
Biocon Q3 FY23 revenue up 36%
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
The company has launched its new range of 25 allopathy ophthalmic products including GUERIMOD, GUERIPRED, BIMATO MST etc. for curing various diseases related to eyes
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
The company has reported total income of Rs. 701 crores during the period ended December 31, 2022
Qure.ai is scaling-up the integration of its AI-powered chest x-ray interpretation tool that can benefit early and easy detection of lung diseases including lung cancer.
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
Investment proposals to the tune of Rs. 54,000 crore has been received in the healthcare and Rs. 17,000 crore has been received in medical education sector
To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
Subscribe To Our Newsletter & Stay Updated
